Treatment of metastatic renal cell carcinoma has radically changed during the last decade with the approval of new drugs, antiangiogenic agents and mammalian targets of rapamycin (m-TOR) inhibitors.
The outcome of metastatic clear-cell carcinoma has been significantly improved, while other entities such as metastatic papillary renal cell carcinoma are still associated with a poor prognosis. To date, there is no standard guideline for metastatic non clear cell carcinoma. We report the case of a 68-year-old patient with a pulmonary metastatic evolution of a papillary kidney cancer who has had more than 3 years disease progression-free survival and is under ongoing treatment with m-TOR inhibitors.
Written by:
Daste A, Gross-Goupil M, Roca S, Bernhard JC, Ravaud A. Are you the author?
Department of Medical Oncology, Hôpital Saint-André, Bordeaux, University Hospital-CHU Bordeaux, 1 Rue Jean Burguet, 33000, Bordeaux, France.
Reference: Target Oncol. 2013 Jan 3. Epub ahead of print.
doi: 10.1007/s11523-012-0245-6
PubMed Abstract
PMID: 23283668
UroToday.com Renal Cancer Section
